Honasa Consumer EBITDA doubles to ₹110 cr in Q1FY27 as revenue grows 32%

3 min read     Updated on 13 Aug 2026, 06:06 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Honasa Consumer reported record Q1FY27 results with revenue up 31.8% YoY to ₹785 crore and EBITDA doubling to ₹110 crore. Margin expansion to 14.1% was driven by mix impact and leverage, while underlying volume growth stood at 30.5%.

powered bylight_fuzz_icon
48170067

*this image is generated using AI for illustrative purposes only.

Honasa Consumer Limited delivered its highest-ever quarterly revenue and profit in the first quarter of fiscal year 2027 (Q1FY27), signaling robust momentum across its digital-first beauty and personal care portfolio. The company, known for brands like mamaearth , The Derma Co., and BTM Ventures, reported a 31.8% year-on-year revenue growth, reaching a record ₹785 crore on a like-for-like (LFL) basis. This top-line expansion was accompanied by significant margin improvement, with EBITDA more than doubling to ₹110 crore.

The financial results, announced on August 13, 2026, highlight a broad-based acceleration across the company’s "House of Brands" strategy. Net profit after tax (PAT) reached an all-time high of ₹90 crore, translating to a PAT margin of 11.5%. The EBITDA margin expanded to 14.1%, up from 7.7% in the prior year period, indicating that the revenue growth is being converted into operating leverage rather than just volume gains.

Brand and Category Performance

The growth was not confined to a single brand but was distributed across core and younger portfolios. Mamaearth accelerated to high-teens growth, driven by its focus categories. Key products such as Rice Dewy Bright Face Wash and Rosemary Anti-Hair Fall Shampoo emerged as primary growth drivers, with Rice Dewy Bright becoming the company’s number one face cleanser. Brand searches for Mamaearth grew 36% year-on-year in Q1FY27.

The Derma Co. crossed the ₹1,000 crore net sales value (NSV) annual recurring revenue (ARR) mark and entered the "teens EBITDA club," making Honasa the only FMCG company in India to build two ₹1,000 crore brands in the last decade. Face cleansers within this brand crossed ₹200 crore ARR. Meanwhile, younger brands grew at over 40%, with traction in Gen Z innovation, premium serums, men’s skincare, hair color, and sunscreen segments.

BTM Ventures, acquired by Honasa, crossed ₹150 crore ARR, growing more than 2x since acquisition. The brand is expanding beyond its South India stronghold into Maharashtra and newer channels, diversifying the company’s geographic and channel risk.

Channel Expansion and New Categories

Offline distribution saw substantial scaling, with both General Trade and Modern Trade growing by over 40%. Outlet coverage has crossed approximately 3 lakh FMCG retail outlets, reinforcing the company’s omnichannel strategy. Focus categories, which include high-growth product lines, grew by more than 35%, driven by strength across key channels. Their contribution to revenue expanded by 450 basis points year-on-year to over 85% in Q1FY27.

Honasa also entered the fragrance category with FIKN, India’s first elixir brand. This move targets a large, underpenetrated category in India, aiming to build a differentiated proposition beyond skincare and haircare. The company emphasized disciplined capital allocation and talent density as it pursues this new category entry.

Financial Highlights

Metric Q1FY27 Q1FY26 YoY Change
Revenue (LFL) ₹785 crore ₹595 crore +31.8%
EBITDA ₹110 crore ₹46 crore +140.7%
EBITDA Margin 14.1% 7.7% +640 bps
PAT ₹90 crore ₹41 crore +116.5%
PAT Margin 11.5% 6.9% +460 bps

A change in settlement by the Flipkart group impacted revenue recognition for Honasa, resulting in a ~₹29 crore impact on the topline with no effect on absolute profitability or contribution margin. Underlying volume growth stood at 30.5%, confirming that the expansion is volume-led. Cash generation reached ₹83 crore, supported by a negative working capital cycle.

What the Numbers Show

The divergence between revenue growth (31.8%) and EBITDA growth (140.7%) underscores significant operating leverage. The margin expansion from 7.7% to 14.1% was driven primarily by mix impact (+300-350 bps), leverage and seasonality (+100-150 bps), and non-recurring items (+150 bps, largely ESOP reversal). This indicates that profitability is scaling disproportionately to top-line growth, a positive signal for unit economics.

Historical Stock Returns for Mamaearth

1 Day5 Days1 Month6 Months1 Year5 Years
+2.58%+4.31%+1.52%+60.22%+78.04%+42.23%

How sustainable is the current 14.1% EBITDA margin given that a significant portion of the expansion was driven by non-recurring ESOP reversals and favorable mix shifts?

What specific challenges might Honasa face in replicating its digital-first success in the offline General Trade segment as it scales beyond 3 lakh outlets?

Will the entry into the fragrance category with FIKN cannibalize existing skincare revenue or successfully capture new consumer spend in India's underpenetrated perfume market?

Mamaearth Q1 Results: Net profit rises 119% YoY to ₹904.5 million

2 min read     Updated on 13 Aug 2026, 06:02 PM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Honasa Consumer Limited posted a 119% YoY jump in net profit to ₹904.48 million for Q1FY26, driven by 27% revenue growth to ₹7,559.46 million. The company also won an arbitration case against its UAE distributor, securing a claim of ₹255.36 million, and approved the acquisition of a majority stake in Fluence Pharma.

powered bylight_fuzz_icon
48169957

*this image is generated using AI for illustrative purposes only.

Honasa Consumer Limited ( mamaearth ) delivered a strong start to FY26, with consolidated net profit after tax rising 119% year-on-year to ₹904.48 million for the quarter ended June 30, 2026. This compares to ₹413.25 million in Q1FY25. Revenue from operations expanded 27% to ₹7,559.46 million, up from ₹5,952.54 million in the corresponding prior period.

The profit surge was driven by robust top-line growth alongside controlled expense management. While total expenses increased to ₹6,592.70 million from ₹5,635.51 million, the profit before tax more than doubled to ₹1,192.44 million from ₹555.93 million. Other income contributed ₹225.11 million, slightly lower than the ₹238.90 million recorded in Q1FY25.

Financial Performance

Metric Q1FY26 Q1FY25 Change
Revenue from operations ₹7,559.46 million ₹5,952.54 million +27.0%
Profit before tax ₹1,192.44 million ₹555.93 million +114.5%
Net profit after tax ₹904.48 million ₹413.25 million +119.0%
Earnings per share (basic) ₹2.77 ₹1.27 +118.1%

Standalone results mirrored the consolidated trend, with net profit reaching ₹843.12 million compared to ₹399.01 million in Q1FY25. Standalone revenue grew 19% to ₹6,963.18 million.

What the Numbers Show

The company’s effective tax rate for the quarter stood at approximately 24.1%, calculated on total tax expenses of ₹287.96 million against a profit before tax of ₹1,192.44 million. This is higher than the implied rate in Q1FY25, where tax expenses were ₹142.68 million on a profit before tax of ₹555.93 million (approx. 25.7%), suggesting a stabilization in tax provisioning despite deferred tax credits in the prior year.

Legal and Strategic Developments

Honasa secured a significant legal victory in its dispute with RSM General Trading LLC, its former overseas distributor. An arbitral tribunal passed a final award in favor of Honasa on May 14, 2026, declaring that RSM breached the arbitration agreement by pursuing proceedings in Dubai courts. The tribunal ordered RSM to pay approximately AED 9.92 million (₹255.36 million) towards various claims filed by Honasa.

The Board of Directors approved the acquisition of a 58% majority stake in Fluence Pharma Private Limited on June 23, 2026, subject to closing adjustments. The remaining 42% stake will be acquired in two tranches over the next five to seven years. Additionally, the company incorporated a wholly owned subsidiary, Honasa Health Private Limited, on July 7, 2026, to handle business-to-consumer nutraceutical operations.

Dividend and Share Capital

The Board recommended a final dividend of ₹3 per equity share for FY26, subject to shareholder approval at the upcoming Annual General Meeting. During the quarter, paid-up equity share capital increased to ₹3,260.24 million from ₹3,253.70 million following the exercise of stock options by employees.

Historical Stock Returns for Mamaearth

1 Day5 Days1 Month6 Months1 Year5 Years
+2.58%+4.31%+1.52%+60.22%+78.04%+42.23%

How will the acquisition of Fluence Pharma and the launch of Honasa Health impact Honasa's revenue mix and profit margins in the upcoming fiscal years?

Will the legal victory against RSM General Trading LLC accelerate Honasa's re-entry strategy into international markets, and which regions are prioritized next?

Can Honasa sustain its current 27% top-line growth trajectory amidst increasing competition in the D2C personal care sector and potential saturation in domestic markets?

More News on Mamaearth

1 Year Returns:+78.04%